HR 9682 United States House · 119th Congress

Cure Hepatitis C Act of 2026

The Cure Hepatitis C Act of 2026 establishes a federal program to eliminate hepatitis C by creating a subscription model that allows the government to purchase antiviral drugs directly from manufacturers and distribute them at no cost to specific patient groups. These groups include individuals in Medicaid or CHIP programs, those without health insurance, patients in correctional facilities, and those receiving care through the Indian Health Service. The bill also expands Medicare coverage by removing deductibles and copayments for hepatitis C treatments between 2028 and 2032. To support these efforts, the legislation authorizes funding for state grants to improve screening and treatment access, mandates the creation of a national strategy and performance dashboard, and requires coordination with various federal agencies and stakeholders.
Bill status in committee 1 of 4 stages cleared
Introduction
Jul 2026
Committee Review
Floor Vote
President
Introduced Jul 14, 2026 Last action Jul 14, 2026
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
2
Key actions
0
Committee
1
Jul 14, 2026
Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Natural Resources, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Jul 14, 2026
Introduced
Introduced in House
lower
1 primary · 4 co-sponsors

Sponsors